Navigation Links
Compendia Bioscience Releases Oncomine Concepts Edition 4.0
Date:3/26/2009

With User Inspired Features and a Redesigned Interface, Oncomine Remains Data-Focused

ANN ARBOR, Mich., March 26 /PRNewswire-USNewswire/ -- Compendia Bioscience announces the release of Oncomine Concepts Edition version 4.0, the latest incarnation of the company's flagship product. Since its inception at the University of Michigan, Oncomine has been rapidly adopted by drug discovery and development organizations looking to improve results of cancer drug development efforts. This new version of Oncomine features an improved user-interface and new export function that allows results sharing.

Cancer researchers and drug developers have made Oncomine the industry-standard, with 15 of the top 20 cancer research companies using this product for interactive access and in-depth analysis of curated cancer genomics data. Oncomine has led to several major cancer research discoveries such as the presence of gene fusions in the majority of prostate cancers (Cancer Cell, Volume 13 Issue 6: June 2008. Nature, Aug 2 2007).

"In accumulating so much high-value data, our biggest success has created our biggest challenge," commented Compendia CEO and Co-founder Dan Rhodes, Ph.D. "It has become difficult to navigate all of the data and analyses to answer the burning questions at hand. Oncomine Concepts Edition 4.0 makes these efforts more intuitive and much, much easier."

New Functionality in Oncomine Concepts Edition 4.0

  • Implementation of the Compendia Ontology - a multi-threaded tree of terms that facilitates searching and browsing data
  • Smart search - the ability to include as many genes as desired in a search request as well as an auto-complete feature using terms from the Compendia Ontology
  • Unified user interface - the ability to view the list of results and individual visualizations within a single browser window
  • Seamless integration of Oncomine Concepts Map - linking drugs, tumor types and biology to sets of genes without leaving the main interface
  • Bookmarks - the ability to save specific searches, results sets or analyses for later review or to share with other Oncomine users
  • Export - the ability to rapidly export results and visualizations to Excel and PowerPoint for further analysis or to share with colleagues

While improved user experience was the driving force in Oncomine Concepts Edition 4.0, the entire Oncomine database was also scrutinized in an effort to standardize and catalog all data points. Oncomine Research Edition 4.0 will be released in the later part of 2009.

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com

About Oncomine(TM)

Oncomine combines a rapidly growing compendium of 30,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm

    For additional information regarding this announcement, please contact:
    John Freshley
    Chief Business Officer
    Compendia Bioscience
    Phone: (734) 945-6344
    E-mail: media@compendiabio.com


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Professionals in bioscience, food-related industries turn to K-State
4. Aeon Bioscience Continues Development of Drug Eluting Stents
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... the launch of Care Management Alerts and Dashboards, an innovative new service enabling ... Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data about ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, ... proposed healthcare bill to repeal and replace the Affordable Care Act (ACA). Like ... make significant cuts to Medicaid, a public health insurance program for low-income children, ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today ... is located at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). ... Restaurant Group who owns three other locations in the Topeka and Bonner Springs, Kan. ...
(Date:6/23/2017)... ... 23, 2017 , ... Georgia State University will host the ... The two-day conference is focused on advancing scientific knowledge about the aggressive triple ... eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” , ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Novavax, Inc., (Nasdaq: NVAX ) today announced ... of its RSV F protein recombinant nanoparticle vaccine candidate (RSV ... published in the journal Vaccine (the ... scientific conferences). The Company previously announced top line results ... the RSV F Vaccine with the goal of protecting infants ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
Breaking Medicine Technology: